CompanyIMTXNasdaqTubingen, 2M

Immatics N.V.

Immatics develops TCR T-cell therapies and TCR bispecific antibodies targeting PRAME for cancers.

SEC EDGAR ClinicalTrials.gov jefferies.com

6-KNov 10Latest SEC filing

Nov 6Latest story

November 2026

Evaxion presents new EVX-01 immune data at SITC, showing ex vivo T-cell detection

Nov 6Clinical readoutBioNTech SE Evaxion Biotech A/SUpdated

October 2026

Imunon agrees to sell ThermoDox rights to VoxelDox Therapeutics

Oct 21Clinical readoutEikon Therapeutics Genmab A/S